NVCR Novocure
Novocure (NVCR) is expected to report earnings on October 22, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.8% since its last earnings release on July 23, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields.
Sector
Healthcare
Industry
Medical Instruments/Supply